Grit Biotechnology Presents Clinical Breakthroughs at 2025 ASCO Annual Meeting
SHANGHAI, May 29, 2025 /PRNewswire/ -- Grit Biotechnology Co., Ltd. ("Grit Bio"), a clinical-stage biotech pioneering novel immunotherapies announced today that three abstracts featuring new clinical data from tumor-infiltrating lymphocytes (TIL)...
Medicilon Passes FDA Inspection, Reinforcing Global R&D Excellence
BOSTON, May 29, 2025 /PRNewswire/ -- On May 20, Medicilon Preclinical Research (Shanghai) LLC ("Medicilon") announces that it has successfully passed an on-site inspection by the FDA. The company receives an official Establishment Inspection Report...
O-RAN ALLIANCE Global PlugFest Spring 2025 Demonstrated Steady Evolution of the O-RAN Ecosystem
O-RAN ALLIANCE Global PlugFests focus on testing and integration to accelerate the development of O-RAN based products and solutions The O-RAN Global PlugFest Spring 2025 advanced O-RAN technology and procedures for testing, deployment and operation...
ETFs Unlock Growth in China's Booming Tech Landscape
GUANGZHOU, China, May 29, 2025 /PRNewswire/ -- In 2025, A-share tech-focused ETFs have continued to attract significant investor interests – the top five industry/thematic ETFs by net inflows, as of May 21, were all technology-related, collectively...
Rona Therapeutics Announces Breakthrough Data on Potential Annual Dosing RNAi Therapy RN026 Targeting Lipoprotein(a) in The National Lipid Association (NLA) Scientific Sessions 2025
SHANGHAI, May 29, 2025 /PRNewswire/ -- Rona Therapeutics, a global leading RNA therapy company, today announced preclinical data for its self-developed RNA interference (RNAi) therapy RN026 at the National Lipid Association (NLA) Annual Scientific...
Neuronata-R® Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis, Moves Toward FDA Accelerated Approval
Meaningful efficacy observed in slow-progressor subgroup; NfL biomarker improvements support potential for accelerated regulatory pathway SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- Neuronata-R®, an autologous bone marrow-derived mesenchymal...
CODIT Launches 'APEC 2025' Policy Monitoring Platform
AI-Powered Legislative Insights: CODIT's Global Evidence-Based Policy Institute strengthens policy research and strategy SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- CODIT, an AI-powered leading GovTech firm, has launched a policy monitoring...
AccurEdit Therapeutics' ART001 Becomes China's First Gene Editing Therapy to Receive FDA Regenerative Medicine Advanced Therapy (RMAT) Designation
RMAT designation expected to expedite development; 72 weeks interim clinical trial data showing sustainable reduction of TTR over 90% with no significant adverse events. SUZHOU, China, May 29, 2025 /PRNewswire/ -- AccurEdit Therapeutics today...